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Background: Mesenchymal stem cells (MSCs) are considered the best candidate in stem cells therapy due to their
multipotent differentiation ability, low expression of co-stimulatory molecules (CD80, CD86, CD34 and HLA-II) and
immunosuppression effects on in vivo immune responses. MSCs were now widely used in clinical trials but received no
encourage results. The major problem was the fate of engrafted MSCs in vivo could not be defined. Some studies
indicated that MSCs could induce immune response and result in the damage and rejection of MSCs. As toll like
receptors (TLRs) are important in inducing of immune responses, in this study we study the role of TLR7 in mediating
the immune status of MSCs isolated from umbilical cord.
Results: Our results indicated that TLR7 agonist Imiquimod could increase the proliferation of PBMC isolated from
healthy human volunteers and release of lactate dehydrogenase (LDH) in supernatant from PBMC-UCMSCs co-culture
system. Flow cytometry and quantitative PCR also confirmed the regulated expression of surface co-stimulatory molecules
and pro-inflammatory genes (IL-6, IL-8, IL-12, TGF-β and TNF-α). And the down-regulation expression of stem cell markers
also confirmed the loss of stemness of UCMSCs. We also found that the osteo-differentiation ability of UCMSCs was
enhanced in the presence of Imiquimod.
Conclusion: To our knowledge, this is the first report that activation of TLR7 pathway increases the immunogenicity of
UCMSCs. Extensive researches have now been conducted to study whether the change of immune status will be help in
tumor rejection based on the tumor-tropism of MSCs.
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Mesenchymal stem cells (MSCs) have demonstrated sig-
nificant potential for clinical use. The advantages of
MSCs in clinical use were due to their easily isolation,
low immunogenicity, immunosuppression effects, lack of
ethical controversy and potential to differentiate into
tissue-specific cell types [1]. MSCs can be successfully
isolated from adipose tissue, liver, tendons, synovial
membrane, amniotic fluid, placenta, umbilical cord and
teeth [2]. MSCs can differentiate easily into mesodermal
phenotypes of adipocyte, osteoblasts, chondrocytes and
some extra-mesodermal cell types including neural, pan-
creatic and hepatocytic phenotypes [3]. The second ad-
vantage of MSCs in cell therapy is the low expression of
co-stimulatory factors including CD80, CD86, HLA-II* Correspondence: weimi003@yahoo.com
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unless otherwise stated.and CD34, which enables MSCs fails to induce immune
responses [4]. The third feature of MSCs is immunosup-
pression effects in that MSCs can inhibit the function of
T cells, B cells, DC and NK cells [5]. All these advan-
tages ensure the benefit of MSCs in clinical trials. MSCs
have been used widely in regenerating damaged tissue
and treat inflammation result from cardiovascular dis-
ease [6], pancreatic regeneration [7], neurological disor-
ders [8], graft-versus-host disease (GVHD) [9] and liver
fibrosis [10].
However, some recent late stage clinical trials have
failed to meet the primary aims, and the fate of MSC fol-
lowing systemic infusion as well as the mechanism they
impact on host biological functions are largely unknown
[11]. Several reports indicated that engrafted MSCs
could induce immune responses in vivo and cause the
rejection or damage of MSCs, such as induction of
memory T cell response [12], increased immunogenicity
of differentiated MSCs [13], enhanced NK cell responseThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dicated that MSCs could not hold immune privilege per-
manently in vivo and might induce immune response
under specific conditions, but large of these mechanisms
remained uncovered.
Toll like receptors (TLRs) are pathogen-associated mo-
lecular patterns (PAMPs) which played important roles in
mediating immune responses, especially recognize invaded
pathogens by binding conserved components of microbes
[16]. There are 11 family members of TLR family which
recognize different pathogens [17]. Previous researches
showed that TLRs were important in mediating MSCs
functions. The expression of TLR1, 2, 5, 9 and 10 were
significantly increased exposure to hypoxic conditions
[18]. Activation of TLR4 pathway protects MSCs from
oxidative stress-induced apoptosis. TLR3 agonist polyI:
C increased the oseteo-differentiation [19] while TLR9
ligand CpG impaired it [20]. However, all these results
of TLRs functions in MSC were from adipogenic tissues
and bone marrow, no evidences were available about
the role of TLRs in biological functions of MSCs iso-
lated from umbilical cord. Although MSCs shared simi-
larities in a lot of biological functions such as metabolic
processes, biological regulation, cell communication
and multicellular processes either from adipose tissues,
bone marrows or from umbilical cord, there were still
obvious differences between MSCs from bone marrow
and umbilical cord [21]. Several embryonic stem cells
(ECS) markers were present in UCMSCs, not in
BMMSCs. UCMSCs expressed SSEA-1, SSEA-3, Oct-4,
TRA-1-60 and DNMT3B, but showed low expression
levels of genes associated with teratomas formation [22].
The UCMSCs were also found expressed higher levels of
pluripotent stem cell genes (Oct-3/4, Nanog, Sox2, Sox17,
Otx2 et al.) than MSCs isolated from bone marrow, adi-
pose tissues and dental pulp [23].Figure 1 Imiquimod increased the proliferation of PBMC and LDH relea
**P <0.001; *P <0.05 versus control group.As previous study indicated the activation of TLR7
increased the leukemia cells and led to the immune re-
jection [24]. In this study, we chose TLR7 to study
whether the activation of TLR7 pathway by specific agon-
ist Imiquimod. The aim of research is to study the role of
TLR7 in regulating the immune status of UCMSCs.Results
Activation of TLR7 pathway of UCMSC by Imiquimod
dramatically increased the proliferation of PBMC
CFSE-labeled leukocytes proliferation was widely used to
detect the increased immune responses in co-culture sys-
tem. In our study, we isolated PBMC from health human
volunteers and co-cultured with UCMSCs in the presence
of Imiquimod, the proliferation of PBMC was 53.3% 72-
hour post stimulation, while the control groups showed
only 10.2% (PBMC+MSC) and 8.5% (PBMC+ Imiqouid),
respectively (Figure 1A). The result strongly suggested the
increased immune response upon TLR7 activation.
Leukocyte-mediated cytotoxicity was a classical method
to assay the LDH levels in culture medium released by
damaged cells. In our experiment, we co-cultured PBMC
with UCMSCs and then added Imiqouid to activate TLR7
pathway, the negative controls were PBMC co-cultured
with UCMSCs without Imiquimod and the PBMC stimu-
lated with Imiquimod. No differences were found among
all three groups 24-hour post co-culture. While signifi-
cantly LDH level was measured 48-hour post Imiquimod
stimulation compared with control group (p < 0.001). The
LDH level reached as high as 61% 72-hour post treatment
in PBMC and UCMSCs co-culture group (p < 0.001), but
the PBMC also showed increased LDH damage upon
Imiquimod stimulation (p < 0.05) (Figure 1B). All these
results confirmed the increased immunogenicity of
UCMSCs activated by TLR7 agonsit Imiquimod.se. A: co-culture of PBMC and UCMSC, B: LDH detection for cytotoxicity.
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co-stimulatory molecules of UCMSCs
CD80, CD86 and HLA-E were the co-stimulator mole-
cules and played important role in immune responses.
Here the flow cytometry detection showed that the ex-
pression of CD80 and CD86 were dramatically in-
creased (48.1% and 36.1%) upon Imiquimod stimulation
72-hour compared with negative control (1.0% and
1.8%) (Figure 2A). While the expression of HLA-E
showed almost no change (1.7% vs 3.1%) (Figure 2A).
We then measured the expression of stem-cell marker
CD29, CD59 and CD90 and found that expression ofFigure 2 Imiquimod enhanced the expression of co-stimulatory facto
molecules, B: surface markers.CD29 and CD90 were inhibited (86.1% and 79.8%) in
the presence of Imiquimod (Figure 2B).
Pro-inflammatory cytokines were induced while the stem
cell markers were inhibited in the presence of TLR7
agonist Imiquimod
The PBMC proliferation and the increased co-stimulatory
molecules upon Imiquimod treatment led us to hypothesize
that activation of TLR7 pathway by Imiquimod could in-
duce the pro-inflammatory molecules which played import-
ant roles in shaping of immune status of UCMSCs.
UCMSCs were treated with Imiquimod and RNA wasrs and inhibted the stem cell surface markers. A: co-stimulatory
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hour post treatment. Quantitative PCR was conducted
to measure the expression variation of important mole-
cules in mediating the immunogenicity of cells. We
found the dramatically induction of several molecules
including NF-κB, TGF-β, TNF-α, IL-1β, IL-6 and IL-12
(all p < 0.001), which were know immune response-
related molecules in increasing the immune responses,
while in INF-β and IL-8 detection the results indicated
that expressions were rapidly increased upon Imiqui-
mod stimulation but decreased at latter time points. In
chemokine detection, CXCL6 and CCL26 showed in-
creased expression while CCL7 and CCL15 were inhib-
ited in the presence of Imiquimod, this contradictory
results indicated the complex effects of TLR7 pathway
on biological functions (Figure 3).
To confirm the influence of Imiquimod on the stem-
ness of UCMSCs, specific stem cells markers (Lin28,
Otx2, Sox2, and Sox17) were tested in this study and the
results indicated the significantly expression inhibition
at latter time points in response to Imiquimod treatmentFigure 3 Imiquimod induced the expression of pro-inflammatory gen
Mean-value from three independent experiments is shown with standard d(Figure 3). The real-time PCR of our study clearly con-
firmed that TLR7 agonist Imiquimod induced the pro-
inflammatory phenotype of UCMSCs and reduced their
stemness.Osteoblasts differentiation ability of UCMSCs was
enhanced by Imiquimod
The conditioned mediums of adipocytes, osteoblasts
and chondrocytes were then added on UCMSCs in the
presence of Imiquimod to test whether the activation of
TLR7 pathway could influence the differentiation ability
of UCMSCs. Different stain methods, as alizarin red for
osteoblasts, safranine for chondrocytes, oil red O for
adipocytes were performed to detect the differentiation sta-
tus of UCMSCs 7-day, 14-day and 21-day post Imiquimod
stimulation. We found that UCMSCs showed enhanced
oste-differentiation ability in the presence of Imiquimod, as
indicated by the calcium deposition (Figure 4A, red ar-
rows). In adipocytes and chondrocytes staining, the
UCMSCs showed no obvious differences betweenes but down-regulated the expression of stem cell markers.
erivation. **P <0.001; *P <0.05 versus control group.
Figure 4 Imiquimod enhanced the osteo-differentiation ability of UCMSCs but had no influence on adipocyte and chondrocyte differentiation.
A: Osteoblasts differentiation, B: chondrocyte differentiation, C: adipocyte differentiation.
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and C).
Discussion
The characteristics of MSCs including multi-potent dif-
ferentiation ability, lack of expression of co-stimulatory
factors and immunosuppressive effect enabled MSCs the
best candidate in cell-based therapy [1]. However, previ-
ous researches indicated the induced immunogenic re-
sponse in vivo against engrafted MSCs under specific
conditions mediated by various molecules [11].
Toll like receptors (TLRs) played important roles in
promoting immune responses. Among 11 members of
TLRs, TLR7 located on the surface of endosome and
could be recognized and activated by ssRNA of RNA vi-
ruses [17]. In leukemia research, activation of TLR7 by
R848 could increase the immunogenicity of acute mye-
loid leukemia cells and result in the rejection of these
cells by host immune response [24]. Previous research
indicated that activation of TLRs did not change the im-
mune status of MSCs, however, our results showed that
TLR7 agonist Imiquimod promoted the immunogenicity
of UCMSCs by increasing the proliferation of human
PBMC in PBMC-UCMSC co-culture system. In support
of this conclusion, the Imiquimod stimulation in
UCMSCs increased the immune attack by human im-
mune cells. Other evidences came from the assay of sur-
face co-stimulatory molecules and gene expression
detection, which indicated the up-regulated expression
of CD80, CD86 and HLA-E on surface of UCMSCs, as
well as the induced expression of pro-inflammatory cy-
tokines (NF-κB, TGF-β, IL-6, IL-12 and TNF-α). The
stem cell markers (Lin28, Otx2, Sox2 and Sox17) were
also found inhibited upon Imiquimod stimulation, which
confirmed the loss of stemness of UCMSCs upon TLR7
activation.
Huang et al. suggested that MSCs were immune privi-
leged in the allogeneic heart in undifferentiated status and
the differentiation of MSCs greatly increased the immune
rejection by the host [13]. Based on this observation, we
hypothesized that increased immunogenicity mediated by
TLR7 pathway was due to the increased differentiation
ability. To demonstrate our hypothesis, we put differenti-
ation medium on UCMSCs to induce the adipocyte,
osteoblast and chondrocyte from UCMSCs. The results
showed that the osteo-differentiation of UCMSCs was
dramatically increased by the Imiquimod stimulation.
Therefore, these data confirmed our hypothesis that the
increased immunogenicity of UCMSCs by TLR7 stemmed
from the enhanced differentiation ability.
It is well known that MSCs can preferentially mobilize
to the sites of inflammation, especially migrate to tumor
tissues [25]. The mechanisms of how chemokines and
cytokines are involved in MSC biological functions stillremains uncovered, and awaits much more research to
clarity. Previous study indicated that CCL5 and SDF-1
secreted by MSCs was responsible for enhancing the
metastatic potential of several breast cancer cells [26].
And monocyte chemotactic protein-1 (MCP-1) secretion
by breast cancer cells was responsible for the homing of
MSCs to tumors, both locally and systemically. Irradi-
ation of tumors released lots of inflammatory mediators,
which played important roles to increase the engraft-
ment of MSCs to the tumor [27].Conclusions
The activation of TLR7 pathway led to the switch of
immune status of UCMSCs might play an important
role in cell-based therapy, as previous report suggested
that MSCs could migrate to the tumor and maintain
the low immune status of tumor environment, finally
protect tumor from immune responses and promote
the tumor progression. So the enhanced immunogen-
icity of UCMSCs might cause the change of immune
status in UCMSCs-tumor environment, which could be
used in tumor therapy.Methods
Isolation, culture and stimulation of UCMSCs
The method to isolate MSCs from umibilical cord was
based on published literature [28]. The umbilical cord was
diced into pieces after disinfection in 75% ethanol for 10–
20 min. The small pieces of mesenchymal tissues were put
into 25 mm2 plates. The culture medium was added when
tissues sticked tightly to the bottom of plates. The dis-
sociated MSCs were collected about 5–8 days after the
mesenchymal tissues were removed. The UCMSCs were
then maintained in Dulbecco’s modified Eagle’s medium
(DMEM, Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS, Invitrogen, Carlsbad,
CA, USA), 2 mM glutamine, 1 mM sodium pyruvate, 100
U/ml penicillin and 100 μg/ml streptomycin and then
stored in liquid for future used.
TLR7 agonist Imiquimod was purchased from IMGE-
NEX (IMG-2207) and dissolved in DMSO at a concen-
tration of 2.5 mg/ml. UCMSCs were seeded into 6-well
plate at a concentration of 1.5 × 105 in 2 ml medium and
Imiquimod was added into the medium at final concen-
tration of 10 μg/ml.Quantitative reverse transcript PCR
The isolation of RNA extraction, cDNA synthesis and the
real-time PCR were performed according to our previous
study [29]. The primers used in QPCR detection were
listed in Table 1.
Table 1 Primer used for real-time PCR
Gene Forward primer Reverse primer GenBank number
IL-1β ACGAATCTCCGACCACCACT CCATGGCCACAACAACTGAC M15330
IL-6 GACCCAACCACAAATGCCA GTCATGTCCTGCAGCCACTG M14584
IL-8 CTGGCCGTGGCTCTCTTG CCTTGGCAAAACTGCACCTT NM_000584
IL-12 CGGTCATCTGCCGCAAA CAAGATGAGCTATAGTAGCGGTCC M65272
IFN-β CAGCAATTTTCAGTGTCAGAAGCT TCATCCTGTCCTTGAGGCAGT M28622
NF-κB AGAGTGCTGGAGTTCAGGATA AAGGTGGATGATTGCTAAGTGT AJ271718
TGF-β TATCGACATGGAGCTGGTGAAG CAGCTTGGACAGGATCTGGC X02812
TNF-α GGTGCTTGTTCCTCAGCCTC CAGGCAGAAGAGCGTGGTG M10988
CXCL6 GCTGAGAGTAAACCCCAAAACG GGAGCACTGCGGGCC NM_002993
CCL7 CTGCTCTCCAGCGCTCTCA GTAAGAAAAGCAGCAGGCGG NM_002984
CCL15 AGCAGAGGCTGGAGAGCTACA GGGTCAGCACAGATCTCCTTGT NM_006273
CCL26 CCTCTCCTGCCTCATGCTTATT CTCTGTCTCTGCATCATTTGTGAA U58914
Lin28 TGCTGTCGAGGGATGGATA CCACCCAATGCGTTCTATTG NM_024674
Otx2 TCGGGCGCAGCTAGATGT TGTCTGGGTACCGGGTCTTG NM_001270525
Sox2 CCCCTTTATTTTCCGTAGTTGTAT GATTCTCGGCAGACTGATTCAA NM_003106
Sox17 TGGCGCAGCAGAATCCA CGACTTGCCCAGCATCTTG NM_022454
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC J04038
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cytotoxicity detection
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from healthy volunteers by density centrifugation
gradient and labeled by carboxyfluorescein diacetate suc-
cinimidyl ester (CFSE) at final concentration of 10 μM.
Pre-cold complete DMEM was added 10 minutes to stop
the reaction. CFSE-Labeled PBMCs were then washed
three times by cold PBS (1200 g, 5-min). PBMCs were
co-cultured with UCMSCs and collected for FACS de-
tection 72-hours in the presence of Imiquimod.
Supernatants from PBMC-UCMSCs co-culture system
were collected 24, 48 and 72-hour post stimulation and
assessed by the cytotoxicity detection kit. Releasing of
LDH from damaged cells was assayed according to the
manual. The lysis percent was calculated by the follow-
ing formula: 100 × (E-M)/(T-M), where E is experimentalTable 2 Monoclonal antibodies for FACS analysis






CD29 eBioscience 17-0299release, M is spontaneous release in the presence of
media alone, and T is maximum release in the presence
of 5% Triton X-100.Surface molecules detection by flow cytometry
UCMSCs, either treated or non-treated with Imiquimod,
were harvested 72-hour post stimulation. The UCMSCs
were then stained with different antibodies to detect sur-
face molecules (Table 2). Flow cytometry was performed
by CXP flow cytometry software. The positive standard
of cells was gated according to the fluorescence intensity
of negative control group.UCMSC differentiation
UCMSCs were seeded into 6-well plate with 1.5 × 105
per well. Conditioned medium of chondrocyte (GIBCO,
A10071-01), osteocyte (GIBCO, A10072-01) and adipo-
cyte (GIBCO, A10070-01) were added in each well,
with 10 μg/ml Imiquimod. And oil-red was used for
staining of adipocyte, alizarin red for osteocyte and
safranine for chondrocyte 7-day, 14-day and 21-day.Data analysis
All data analysis and figures completion was the same
with our previous study [29].
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